A groundbreaking study led by Oregon State University has shed light on the remarkable effects of certain polyunsaturated fatty acids in combating a life-threatening liver condition, opening doors to novel drug research in an area where no FDA-approved medications currently exist.
How might the identification of betacellulin as a target for omega-3 polyunsaturated fatty acids inspire personalised treatments?